SS Innovations International (NASDAQ: SSII) showcased its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console at two international medical conferences in October 2026, demonstrating the feasibility of long-distance robotic surgery. The demonstrations signal a step toward extending specialist surgical expertise beyond major medical centers, though broad adoption will depend on clinical validation, connectivity, and regulatory approvals.
At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, Chairman and CEO Dr. Sudhir Srivastava performed a robotic-assisted atrial septal defect procedure on a patient located approximately 7,500 miles away in Bengaluru, India. The operation highlighted the SSi Mantra system’s tele-surgery capabilities, which the company detailed in its announcement (https://ibn.fm/EZFDT). Four additional robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric, and gynecological procedures.
As of October 23, 2026, SS Innovations reported 205 telesurgeries performed with the SSi Mantra system, including cardiac procedures. The milestone underscores the growing volume of remote robotic operations, but the company acknowledges that widespread adoption hinges on clinical validation, connectivity, and regulatory requirements. For patients and hospitals, the technology could eventually mean access to specialized surgical care regardless of geographic distance, potentially reducing travel and wait times for complex procedures.
SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027. The timeline remains subject to the FDA’s review. FDA clearance would mark a critical step for the company’s entry into the U.S. market, one of the largest for surgical robotics, and could intensify competition in the sector. The company’s progress is closely watched by investors and industry analysts; more information is available through SS Innovations (NASDAQ: SSII).
The demonstrations at EACTS and the Society of Robotic Surgery India conference place SS Innovations among a small group of companies advancing remote robotic surgery. While the concept promises to democratize access to expert care, questions about latency, patient safety, and liability remain. The company’s reported 205 telesurgeries provide a foundation for further clinical study, but independent validation will be essential for regulatory acceptance and payer coverage.
For the medical industry, successful remote robotic surgery could reshape referral patterns and create new models of care delivery. Hospitals might leverage tele-surgery to offer specialized procedures without recruiting on-site specialists, while device makers could see demand for advanced consoles and connectivity solutions. However, the infrastructure requirements—reliable high-speed links and redundant systems—pose significant hurdles, particularly in underserved regions.
SS Innovations’ forward-looking statements carry risks and uncertainties, and actual results may differ materially. The company’s path to FDA clearance and commercial adoption will be closely monitored as it seeks to translate these demonstrations into routine clinical practice. The original release is available via www.newmediawire.com.
